NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
- Stopped Trial terminated Sponsor's reason: Sponsor decision
- Final enrollment: 3 participants, 2% of the 190 planned
- Eligibility criteria expanded, about 8 words
- Primary completion date changed from estimate of May 2029 to Oct 19, 2026
- Minor Enrollment closed, study ongoing
- Site details revised at 9 of 9 sites
- Minor Study sites: 8 to 9v9
- Minor Study sites: 7 to 8v8
- Minor Study sites: 6 to 7v7
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 4 to 6v6
- Minor Study sites: 3 to 4v5
- Minor Study sites: 2 to 3v4
- Minor Study sites: 1 to 2v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 2026 to Jan 9, 2026
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and tolerability of AB-3028
Timeframe: From AB-3028 infusion up to 24 months post-infusion
Arms and interventions
AB-3028Experimental
Patients receive a single dose of AB-3028 intravenously on day 0.
Biologicals: AB-3028
Sites
9 sites in 1 country